FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089970850> ?p ?o ?g. }

• W2089970850 endingPage "103" @default.
• W2089970850 startingPage "89" @default.
• W2089970850 abstract "Pancreatic enzyme replacement therapy (PERT) is essential for maintaining adequate nutrition in children with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The US Food and Drug Administration regulations now require all PERT products to undergo clinical efficacy and safety studies before they can be considered for marketing approval.This study was conducted to compare the efficacy of a new formulation of pancrelipase (pancreatin) delayed-release 12,000-lipase unit capsules with placebo in children with EPI due to CF.This was a multicenter, randomized, double-blind, placebo-controlled, 2-period crossover, superiority study of the new formulation of pancrelipase delayed-release 12,000-lipase unit capsules in children aged 7 to 11 years with CF and EPI. In each period, pancrelipase or identical placebo capsules were taken for 5 days. The primary outcome measure was the coefficient of fat absorption (CFA); secondary outcome measures were the coefficient of nitrogen absorption (CNA) and clinical symptoms. The latter were assessed based on patient-reported daily stool frequency, stool consistency (hard, formed/normal, soft, or watery), flatulence (none, mild, moderate, or severe), and abdominal pain (none, mild, moderate, or severe). Safety measures included vital signs, physical examinations, standard laboratory safety tests (hematology and biochemistry), and adverse events.Seventeen patients were randomized to treatment and 16 completed the study; 1 patient withdrew consent during the first treatment period and was not included in the efficacy analysis. Patients' median age was 8.0 years (range, 7-11 years); 12 patients (70.6%) were male. CFA values were significantly greater for pancrelipase compared with placebo, with least squares mean (SE) values of 82.8% (2.7%) and 47.4% (2.7%), respectively (P < 0.001). The results were similar for CNA, with mean values of 80.3% (3.2%) and 45.0% (3.2%) (P < 0.001). Pancrelipase treatment had significantly greater effects on CFA and CNA in patients with a placebo CFA <50% than in those with a placebo CFA >50% (both parameters, P < 0.001 and P = 0.008, respectively). Significant improvements in stool fat, weight, and nitrogen and a significant reduction in daily stool frequency were observed with pancrelipase compared with placebo (all, P < 0.001). Symptoms of EPI were less severe and remained relatively stable during pancrelipase treatment, but worsened slightly during receipt of placebo. Treatment-emergent adverse events were reported in 5 patients (29.4%) during receipt of pancrelipase and in 9 patients (56.3%) during receipt of placebo; these were predominantly gastrointestinal events. There were no discontinuations due to treatment-emergent adverse events and no serious adverse events.In this study in children with EPI due to CF, the new formulation of pancrelipase delayedrelease capsules was associated with improvements in CFA, CNA, stool properties, and EPI symptoms compared with placebo. Pancrelipase delayed-release capsules appeared to be well tolerated. ClinicalTrials.gov identifier: NCT00690820. (Clin Ther." @default.
• W2089970850 created "2016-06-24" @default.
• W2089970850 creator A5019605846 @default.
• W2089970850 creator A5021777025 @default.
• W2089970850 creator A5022734211 @default.
• W2089970850 creator A5042557738 @default.
• W2089970850 creator A5043969468 @default.
• W2089970850 creator A5051055602 @default.
• W2089970850 creator A5072622854 @default.
• W2089970850 date "2010-01-01" @default.
• W2089970850 modified "2023-10-01" @default.
• W2089970850 title "Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: A multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study" @default.
• W2089970850 cites W1426259424 @default.
• W2089970850 cites W1549620506 @default.
• W2089970850 cites W1970963921 @default.
• W2089970850 cites W1971316765 @default.
• W2089970850 cites W1983061964 @default.
• W2089970850 cites W1983928112 @default.
• W2089970850 cites W1985809072 @default.
• W2089970850 cites W2022687215 @default.
• W2089970850 cites W2031968580 @default.
• W2089970850 cites W2033160596 @default.
• W2089970850 cites W2035348164 @default.
• W2089970850 cites W2037028624 @default.
• W2089970850 cites W2049236612 @default.
• W2089970850 cites W2051745786 @default.
• W2089970850 cites W2055709238 @default.
• W2089970850 cites W2055855735 @default.
• W2089970850 cites W2061909665 @default.
• W2089970850 cites W2066212396 @default.
• W2089970850 cites W2079170831 @default.
• W2089970850 cites W2089511652 @default.
• W2089970850 cites W2097796797 @default.
• W2089970850 cites W2152312418 @default.
• W2089970850 cites W2170363361 @default.
• W2089970850 cites W2883575878 @default.
• W2089970850 cites W4211074500 @default.
• W2089970850 cites W44953547 @default.
• W2089970850 doi "https://doi.org/10.1016/j.clinthera.2010.01.012" @default.
• W2089970850 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20171415" @default.
• W2089970850 hasPublicationYear "2010" @default.
• W2089970850 type Work @default.
• W2089970850 sameAs 2089970850 @default.
• W2089970850 citedByCount "53" @default.
• W2089970850 countsByYear W20899708502012 @default.
• W2089970850 countsByYear W20899708502013 @default.
• W2089970850 countsByYear W20899708502014 @default.
• W2089970850 countsByYear W20899708502015 @default.
• W2089970850 countsByYear W20899708502016 @default.
• W2089970850 countsByYear W20899708502017 @default.
• W2089970850 countsByYear W20899708502018 @default.
• W2089970850 countsByYear W20899708502019 @default.
• W2089970850 countsByYear W20899708502020 @default.
• W2089970850 countsByYear W20899708502021 @default.
• W2089970850 countsByYear W20899708502022 @default.
• W2089970850 countsByYear W20899708502023 @default.
• W2089970850 crossrefType "journal-article" @default.
• W2089970850 hasAuthorship W2089970850A5019605846 @default.
• W2089970850 hasAuthorship W2089970850A5021777025 @default.
• W2089970850 hasAuthorship W2089970850A5022734211 @default.
• W2089970850 hasAuthorship W2089970850A5042557738 @default.
• W2089970850 hasAuthorship W2089970850A5043969468 @default.
• W2089970850 hasAuthorship W2089970850A5051055602 @default.
• W2089970850 hasAuthorship W2089970850A5072622854 @default.
• W2089970850 hasConcept C126322002 @default.
• W2089970850 hasConcept C142724271 @default.
• W2089970850 hasConcept C168563851 @default.
• W2089970850 hasConcept C197934379 @default.
• W2089970850 hasConcept C202061045 @default.
• W2089970850 hasConcept C204787440 @default.
• W2089970850 hasConcept C27081682 @default.
• W2089970850 hasConcept C2775913212 @default.
• W2089970850 hasConcept C2776938444 @default.
• W2089970850 hasConcept C2777152358 @default.
• W2089970850 hasConcept C2778375690 @default.
• W2089970850 hasConcept C2991744798 @default.
• W2089970850 hasConcept C535046627 @default.
• W2089970850 hasConcept C71924100 @default.
• W2089970850 hasConcept C87813604 @default.
• W2089970850 hasConcept C90924648 @default.
• W2089970850 hasConceptScore W2089970850C126322002 @default.
• W2089970850 hasConceptScore W2089970850C142724271 @default.
• W2089970850 hasConceptScore W2089970850C168563851 @default.
• W2089970850 hasConceptScore W2089970850C197934379 @default.
• W2089970850 hasConceptScore W2089970850C202061045 @default.
• W2089970850 hasConceptScore W2089970850C204787440 @default.
• W2089970850 hasConceptScore W2089970850C27081682 @default.
• W2089970850 hasConceptScore W2089970850C2775913212 @default.
• W2089970850 hasConceptScore W2089970850C2776938444 @default.
• W2089970850 hasConceptScore W2089970850C2777152358 @default.
• W2089970850 hasConceptScore W2089970850C2778375690 @default.
• W2089970850 hasConceptScore W2089970850C2991744798 @default.
• W2089970850 hasConceptScore W2089970850C535046627 @default.
• W2089970850 hasConceptScore W2089970850C71924100 @default.
• W2089970850 hasConceptScore W2089970850C87813604 @default.
• W2089970850 hasConceptScore W2089970850C90924648 @default.
• W2089970850 hasFunder F4320333783 @default.
• W2089970850 hasIssue "1" @default.

• next